Perturbations of the p53 pathway are associated with more aggressive and therapeutically
refractory tumors. However, molecular assessment of p53 status, by using sequence analysis …

The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …

Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (…

Background: Histologic grade in breast cancer provides clinically important prognostic
information. However, 30%–60% of tumors are classified as histologic grade 2. This grade is …

Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …

Background: A 70-gene signature was previously shown to have prognostic value in
patients with node-negative breast cancer. Our goal was to validate the signature in an …

Background Trastuzumab—a humanised monoclonal antibody against HER2—has been
shown to improve disease-free survival after chemotherapy in women with HER2-positive …

Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …

Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in
lymph node–negative (N − ) breast cancer patients was reported. The aims of this study …